Duke-NUS Medical School, GenScript Biotech Corporation and Singapore’s Agency for Science, Technology and Research (A*STAR) have announced an exclusive agreement to co-develop and manufacture a serological Covid-19 antibody test that allows rapid detection of neutralising antibodies (NAbs).

NAbs are present in the serum of Covid-19 patients and are responsible for clearing the viral infection.

While there are now many Covid-19 antibody test kits available, this is the first that is capable of measuring NAbs, which usually requires the use of live virus cells, highly skilled operators and complex laboratory procedures that are generally less sensitive and require several days to obtain results.

The new test, known as cPass, can be rapidly conducted within an hour in most research or clinical labs.